Business Context and Reporting Period
Oramed Pharmaceuticals Inc. (ORMP) filed this Form 8-K on August 27, 2020, reporting an event that occurred on August 21, 2020. The company is a Delaware corporation with principal executive offices in New York, New York, and its common stock trades on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a specific dispute:
- Disputed Payment Obligation: The company estimates the amount in dispute to be between $2 million and $6 million.
Material Changes
The material change reported is the receipt of a letter from Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) disputing certain payment obligations under the Amended and Restated Technology License Agreement dated December 21, 2015. Oramed Pharmaceuticals wholly disputes these claims.
Outlook, Risks, and Management Commentary
Management states that the parties are currently in discussions to reach a mutually agreeable solution. The filing includes a warning concerning forward-looking statements, noting that the estimated amount of the payment obligation is based on current expectations and is subject to uncertainties. The actual amount in dispute may differ materially from the company's estimate. The company undertakes no obligation to publicly release revisions to these statements.
Key Facts for Investor Verification
- Verify the status of ongoing discussions between Oramed and HTIT regarding the disputed license agreement payments.
- Monitor for any legal proceedings or formal litigation arising from the dispute.
- Confirm the final determination of the disputed amount, which is currently estimated between $2 million and $6 million.
- Review the original Amended and Restated Technology License Agreement dated December 21, 2015, to understand the underlying payment terms.